viewAnteris Technologies Ltd

Admedus heart valve device in development passes key milestone

The company has applied its ADAPT tissue technology to develop the TAVR device.

Arm supports the heart concept design
Transcatheter aortic valve replacement (TAVR) eliminates the need for open-heart surgery

Admedus Ltd (ASX:AHZ) has passed a key development milestone for its transcatheter aortic valve replacement (TAVR) device project.

TAVR is where a valve is placed into the heart via a catheter (usually inserted through the leg) to replace the aortic valve, eliminating the need for open-heart surgery.

The US$3.5 billion market is expected to grow to US$7.5 billion by 2024.

Admedus’s TAVR device has advantages over current products

Current TAVR products on the market contain three separate pieces of tissue held together by more than 100 sutures.

In comparison, the Admedus TAVR prototype device is a uni-body 3D moulded aortic valve design.

Durability benchmark of 200 million cycle tests completed

The TAVR device project passed a key developmental milestone by achieving the durability benchmark of 200 million cycle tests.

Wayne Paterson, CEO, said: “Passing the 200 million valve cycle test is a critical step in this pre-clinical stage of development as it confirms the valve meets the required standard of durability - fundamental to the overall viability and progression of the project.

“There’s still a lot of work to be done in the development and testing phases but successfully completing the cycle durability test gives us the green light to continue our investment in this strategically important initiative.

“If successful, the Admedus TAVR will reinvent the way these devices are used and manufactured.”

READ: Admedus enters agreement opening sales channel to 1,500 hospitals

Recently, Admedus entered a purchasing agreement allowing it to promote its flagship ADAPT® tissue products, CardioCel® and VascuCel®, to more than 1,500 hospitals.

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

Market: ASX
Market Cap: $23.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read